Diligence memo · auto-generated · as of July 2, 2026

Pharma Acuity, Inc.

Pharma Acuity, Inc. looks over-valued against its niche peers and is at-risk on financing cadence.

WatchOverdue for a raise versus sector cadence — could be a bridge, a down round, or distress. Watch for the next filing.

Businessfiled

Pharma Acuity, Inc. operates in Pharma, based in OLD GREENWICH.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Pharma Acuity, Inc. has raised $500K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $500K on 2023-08-01.

Most recent recorded round closed around 2023-08-01.

Valuation (modeled)modeled

Provath models Pharma Acuity, Inc. at approximately $3.9M (range $280K–$17M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 1.63× the median modeled value of Pre-Seed Pharma companies in 2022–2024 (15 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Last raise 2.9 yr ago; this sector typically re-raises about every 16 months.

Past due for a raise versus sector cadence — watch for distress or a bridge.

Comparablesmixed

Capital scale ranks ahead of 30% of Pharma peers (310 compared).

Modeled value ranks above 25% of those peers.

Closest niche peers: Acanna Therapeutics, Inc., Neural Therapeutics Inc., Insignis Therapeutics Inc., Atacama Therapeutics, Inc., Arena Therapeutics OpCo, Inc..

Peoplefiled

1 named person on file across officers, directors and signatories.

Risks & flagsmixed

Overdue for a raise versus sector norm — distress or bridge risk.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.